title: Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program.
authors.affiliation: Medical Practices Evaluation Center, Massachusetts General Hospital, Boston 02114, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Barry
authors.forename: C
authors.initials: C
authors.lastname: Fleming
authors.forename: C M
authors.initials: CM
authors.lastname: Coley
authors.forename: J H
authors.initials: JH
authors.lastname: Wasson
authors.forename: M C
authors.initials: MC
authors.lastname: Fahs
authors.forename: J E
authors.initials: JE
authors.lastname: Oesterling
mesh_terms: D000368:Aged; D003362:Cost-Benefit Analysis; D006801:Humans; D008297:Male; D006278:Medicare / Q000191:economics*; D008962:Models, Theoretical; D015397:Program Evaluation; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology; D012306:Risk; D013997:Time Factors; D014481:United States
chemical_list: D017430:Prostate-Specific Antigen